Plant Name: Lepidium apetalum
Taxonomic Information:
Plant ID: NPO11097
Plant Latin Name: Lepidium apetalum
Taxonomy Genus: Lepidium
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
153459
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
India; ChinaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Antiasthmatic; Antibacterial; Antitussive; Cardiotonic; Diuretic; Expectorant; Purgative
Geographical Distribution:
India; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| MIF; ALOX12; HSD17B10; NOX4; ALOX15; POLB; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA7; CA4; | |
| FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.708E-09 | 1.859E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.256E-08 | 1.215E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.662E-07 | 2.178E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.238E-06 | 6.741E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.238E-06 | 6.741E-04 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.809E-06 | 8.752E-04 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.339E-06 | 1.061E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 3.646E-06 | 1.444E-03 | ALOX15, AXL, CYP1A1, CYP1B1, FABP4, FLT3, IGF1R, KDR, NOX4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.712E-06 | 1.444E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.712E-06 | 1.444E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.712E-06 | 1.444E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.602E-06 | 1.936E-03 | ALOX12, CA12, CA2, CA7, FABP4, MET, NOX4, NPSR1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.236E-05 | 3.686E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.764E-05 | 4.862E-03 | CYP1A1, CYP1B1, NOX4 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 2.591E-05 | 6.270E-03 | FLT3, KDR |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.895E-05 | 6.928E-03 | AURKB, CDK1, POLB |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.952E-05 | 6.988E-03 | ALOX12, ALOX15, CYP1A1, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.910E-05 | 8.777E-03 | ALOX12, CDK1, FLT3, IGF1R, KDR, MIF, PIM1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.422E-05 | 9.471E-03 | AXL, CDK1, CYP1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.588E-09 | 1.682E-07 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.190E-05 | 7.116E-04 | CYP1A1, CYP1B1, IGF1R |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.882E-04 | 6.244E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
